Loading
Every dated change on the records linked to Undifferentiated pleomorphic sarcoma (UPS), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Standard arm DFS HR ~0.
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.